ICER Publishes Evidence Report on Therapies for High Cholesterol

January 22, 2021

This morning ICER issued the Evidence Report assessing the comparative clinical effectiveness and value of inclisiran (Novartis), bempedoic acid (Nexletol®, Esperion Therapeutics), and bempedoic acid/ezetimibe (Nexlizet™, Esperion Therapeutics) for treating heterozygous familial hypercholesterolemia and for secondary prevention of atherosclerotic cardiovascular disease.

The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a less frequent regimen that may enhance therapy adherence; ICER recommends an annual health-benefit price benchmark range of $3,600-$6,000. Also, bempedoic acid provides a new oral treatment option that may be helpful particularly for patients who are not able to take statins; however, a discount of at least 36% discount off its list price would be needed to reach the top end of our benchmark range of $1,600-$2,600 per year. ICER will be hosting a public meeting to discuss these findings on February 5. Read more here.

Share This Story!